Researchers find how ovarian tumor affects immune system Baltimore Examiner, MD - More than 20000 US women were diagnosed with ovarian cancer in 2004, and 14716 women died from the disease. The Hopkins researchers? findings may also aid ...
Cancer hotline seeks survivors Troy Record, NY - Women may shrug them off and may even be misdiagnosed at first. About 75 percent of women are diagnosed with late-stage ovarian cancer. ...
Why some early breast cancers may spontaneously disappear CTV.ca, Canada - Nov 30, 2008 Given that approximately two out of three breast cancer tumours are estrogen-driven, the sudden drop-off in ovarian estrogen at menopause may starve those ...
Research: Some Cancer May Disappear By Itself WJZ, MD - Nov 25, 2008 "I'm having chemotherapy because I have ovarian cancer and I've had it since 1998," she said. She wasn't supposed to make it into her sixties. ...
Myriad Genetics: Profits In Predictive Medicine istockAnalyst.com (press release), OR - MYGN has tests for a predisposition for breast cancer, ovarian cancer, melanoma, and colorectal cancer. "Using the specific genetic characteristics of an ...MYGN
Pregnant, two kids under five... and cancer. What would you do? guardian.co.uk, UK - Nov 29, 2008 Some studies show an increase (mostly of ovarian cancer) among women treated for infertility; others show a decrease. It may be that the underlying causes ...
Thalidomide For Ovarian Treatment Oneindia, India - Nov 22, 2008 What all of this means is that while thalidomide may not cure ovarian cancer, it may broaden the treatment options available to physicians and provide more ...
Source: Google News
Recent News and Articles on the Keywords: ovarian + cancer + protein Related to the article below (Last Update: 8/7/2008)
Craig W. Philips Takes Helm at CTI FOXBusiness - Aug 5, 2008 OPAXIO is also being studied independently in a phase III trial for ovarian cancer, with interim data results expected in late 2009. ...CTIC - OTC:CMTX
Breast cancer: What you need to know Food Consumer, IL - Aug 5, 2008 Soy and Broccoli: 3, 3-Diindolylmethane and genistein found in broccoli and soy respectively may help prevent the spreading of breast cancer and ovarian...
Abracadabra! Nanoparticles Make Cancer Cells Rise Discovery Technology, MD - Jul 31, 2008 Those metallic pieces are attached to a protein that only binds to a specific protein found on the surface of ovarian cancer cells. ...
Tikcro Technologies Closes Funding into BioCancell Business Wire (press release), CA - Jul 31, 2008 preparing for a multi center Phase I/IIa clinical trial for the treatment of ovarian cancer. - Ongoing experimental treatment of ovarian cancer conducted ...OTC:TIKRF - TLV:BICL
Many herbs make move to medicine cabinet MLive.com, MI - Aug 5, 2008 Researchers studying colon and ovarian cancers at the University of Minnesota and University of Michigan suggest ginger may be able to stop the progression ...
New Treatment for Ovarian Cancer Discovered Associated Content, CO - Jul 16, 2008 ... named TG2 (transglutaminase G2), is associated with ovarian cancer. TG2 is a protein. When this TG2 protein is expressed abundantly by the organism it ...
Source: Google News
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 - Y Miki, J Swensen, D Shattuck-Eidens, PA Futreal, … - Science, 1994 - sciencemag.org ... This protein contains a zinc finger domain in its amino-terminal region ... BRCA1 should
facilitate early diagnosis of breast and ovariancancer susceptibility in ...
Use of proteomic patterns in serum to identify ovarian cancer - EF Petricoin, AM Ardekani, BA Hitt, PJ Levine, VA … - The Lancet, 2002 - Elsevier ... The protein peak at M/Z 2111 identified by the algorithm as belonging to the optimum ... Cancer, Unaffected, New cluster. ... No evidence of ovarian cysts, 2/24, 22/24, 0 ...
Folate-binding protein is a marker for ovarian cancer - IG Campbell - Cancer Research, 1991 - AACR ... American Association for Cancer Research. ARTICLES. Folate-binding protein
is a marker for ovariancancer. IG Campbell, TA Jones, WD ...
p53 gene mutations and protein accumulation in human ovarian cancer. - J Kupryjanczyk, AD Thor, R Beauchamp, V Merritt, … - Proceedings of the National Academy of Sciences of the …, 1993 - pubmedcentral.nih.gov ... 11): 4961?4965. Copyright notice. p53 gene mutations and protein accumulation
in human ovariancancer. J Kupryjanczyk, AD Thor ...
The genetic attributable risk of breast and ovarian cancer. - EB Claus, JM Schildkraut, WD Thompson, NJ Risch - Cancer, 1996 - ncbi.nlm.nih.gov Cancer. 1996 Jun 1;77(11):2318-24. The genetic attributable risk of breast and ovariancancer. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. ...
Researchers at Penn State College of Medicine found a signal that could lead to earlier detection and treatment of ovarian cancer.
The Penn State team of scientists led by principal investigator Kathleen M. Mulder, studied "km23," a protein that helps to direct protein traffic in the cell.
Mulder's team has found that at least 42 percent of ovarian cancer patient tumor tissues have alterations in km23.
No similar alterations in km23 were detectable in normal human tissues, suggesting that it may be both a diagnostic indicator for the development of ovarian cancer and a possible target for cancer therapies.
" While only close to half of ovarian cancer patients may have defects in km23, our results are still highly significant because there is no clinically useful screening test available for detection of ovarian cancer," said Mulder.
Additional studies are under way to continue the analyses of km23 abnormalities in specimens from women with ovarian cancer, and to determine whether different km23 alterations exist in other solid tumors, such as breast and colon cancer.
" The next step is to develop a screening test for early detection of the km23 alterations in the blood of ovarian cancer patients," Mulder said.
In addition, studies are under way to develop drugs that would target km23 and override the defects caused by the km23 alterations in the cancer cells.
" The plan is to be able to use the screening test to identify those patients who would benefit from the anti-cancer drugs we will be developing using km23 as the target," Mulder said. " In the pharmaceutical industry, this is often referred to as 'personalized medicine,' meaning that each patient can be checked for alterations in specific genes and their treatment targeted for the alterations specific to their cancer."
Epithelial ovarian cancer is often diagnosed at an advanced stage and accounts for more than 16,000 deaths annually.
Despite advances in surgical techniques and chemotherapy, overall survival rates for women with ovarian cancer have not improved significantly because of late detection, often after the disease has already spread to remote organs.
The identification of a potential early warning signal and a possible therapeutic target for the disease could lead to improved survival rates.
km23 is responsible, in part, for the movement of cellular proteins along microtubules, the "highways" of the cell. The cellular proteins, or "cargo," are actually driven along the microtubules by "motors" in the cell. km3 helps to connect the right cargo to the motor so that the cargo can reach its appropriate destination.
In a previous study, Mulder and her team found that the process is initiated by the binding of a factor called "TGFß" to receptors on the cell's surface. This, in turn, sends a signal to km23 telling it to attach to the motor and pick up the cargo. When km23 is altered, the cargo doesn't reach the correct destination in the cell. As a result, a traffic jam occurs, which causes chaos in the cell.
" TGFß is a critical regulator of cell growth and is present throughout the body," she said. " It is already known to play an important role in suppressing the growth of epithelial cells, the type of cell that gives rise to solid tumors. When the appropriate signals are not sent by TGFß, the growth of epithelial cells will not be controlled and a solid tumor can form. The alterations in km23 appear to disrupt some of the normal signals sent by TGFß."
" The km23 alterations we have identified in human ovarian tumor tissues, described in our recent report, might also be used as prognostic indicators to help physicians decide on the most appropriate treatment for each patient," Mulder said.
